Publication
“AI and sustainability - cure or curse?”
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Global | Publication | April 2016
Case: Apotex Inc., et al. v. Merck & Co. Inc., et al. (SCC docket no. 36655)
Drug: MEVACOR® (lovastatin)
Nature of case: Leave to appeal from damages decision following a declaration that Canadian Patent No. 1,161,380 (380 Patent) was valid and infringed
Successful party: Merck & Co. Inc. and Merck Canada Inc.
Date of decision: April 14, 2016
On April 14, 2016, the Supreme Court of Canada (SCC) dismissed Apotex Inc. and Apotex Fermentation Inc.’s (Apotex) application for leave to appeal a Federal Court of Appeal (FCA) decision upholding a damage award for infringement of a patent relating to lovastatin. The FCA held that a non-infringing alternative (NIA) defence is legally relevant when assessing damages, but that Apotex failed to establish on the evidence that it could and would have pursued the NIA in the “but for” world.
As we previously reported, in the liability phase, the Trial Judge found that Apotex infringed the 380 Patent for a method for making lovastatin using a microorganism of the genus Aspergillus terreus (AFI-1). The trial decision was confirmed by the FCA. In the damages phase, the Federal Court (FC) found that Merck was entitled to a total damages award of $119,054,327, plus pre-judgement and post-judgement interest, and rejected Apotex’s arguments that the existence of an NIA is a relevant factor in the assessment of damages.
Apotex appealed the decision on multiple grounds, including that the FC erred by rejecting the legal relevance of non-infringing lovastatin when computing damages, and that the damages for which it is liable should be reduced because it had a NIA available. The FCA held that the availability of an NIA is relevant in law when assessing the patentee’s lost sales. However, while Apotex established that it had a real and viable NIA, the FCA found that the evidence did not support Apotex’s contention that it could and would have pursued its NIA in the “but for” world. The FCA dismissed Apotex’s appeal with costs.
As a result of the SCC’s dismissal of Apotex’s appeal, the FCA decision has been affirmed: an NIA defence is available as a matter of law in the assessment of damages subject to being established on the facts of each case.
SCC docket 36655 may be found here.
Publication
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023